Trending News

US Tariff and Trade Update: Temporary Pause on Canada and Mexico, Tariffs on China, China Retaliation, and What's Next

Tariffs Paused in Mexico and Canada, but not China

Funding Freeze for Health Care Providers – What You Need to Know

FTC Announces Updates to COPPA Rule

Video Game Maker to Pay $20 Million to Settle FTC COPPA Enforcement Action

FTC Announces New HSR Notification Thresholds for 2025

Ceramtec GMBH v. Coorstek Biocermanics LLC

FTC Finalizes Long-Awaited Updates to Children's Privacy Rule

FTC Finalizes Changes to Children's Privacy Rule

DOE Announces Intent to Fund R&D to Advance Biofuels and Bioproducts

GlobeNewswire Biotech

Website

www.globenewswire.com

Featured Biotech Press Releases From GlobeNewswire

Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation
Posted On Tuesday, February 11, 2025
LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement
Posted On Tuesday, February 11, 2025
Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
Posted On Tuesday, February 11, 2025
RxTechExam and Pennsylvania Pharmacists Association Join Forces to Launch Technician Training Program Ahead of Regulatory Changes
Posted On Tuesday, February 11, 2025
Crinetics Pharmaceuticals Announces February 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Posted On Tuesday, February 11, 2025
Beyond Air® Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update
Posted On Tuesday, February 11, 2025
BioAstra Unveils "Twin Astra": Pioneering Deep-Space Medical Research Program Set to Transform Space Exploration and Earth-Based Medicine
Posted On Tuesday, February 11, 2025
Revolo to Present at the 2025 AAAAI / WAO Joint Congress
Posted On Monday, February 10, 2025
Cogent Biosciences Announces Bezuclastinib Poster in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2025 AAAAI Annual Meeting
Posted On Monday, February 10, 2025
Capricor Therapeutics to Participate in Upcoming Investor Conferences
Posted On Monday, February 10, 2025
Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis
Posted On Monday, February 10, 2025
BioCryst to Present New ORLADEYO® (berotralstat) Results from APeX-P Pediatric Trial at 2025 American Academy of Allergy, Asthma & Immunology / World Allergy Organization Joint Congress
Posted On Monday, February 10, 2025
Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis
Posted On Monday, February 10, 2025
Achieve Life Sciences Announces Positive Outcome of Second Data Safety Monitoring Committee Review for the ORCA-OL Clinical Trial
Posted On Monday, February 10, 2025
Oncocyte Prices $29.1 Million Equity Offering
Posted On Monday, February 10, 2025
Intelligent Bio Solutions Releases Shareholder Letter Detailing 2024 Growth and 2025 U.S. Expansion Strategy
Posted On Monday, February 10, 2025
Avid Bioservices Launches New Company Website Designed to Boost Company Brand Awareness and Enhance the Visitor Experience
Posted On Monday, February 10, 2025
IMUNON Appoints Douglas V. Faller, M.D., Ph.D., as Chief Medical Officer
Posted On Monday, February 10, 2025
Ashvattha Presents Positive Phase 2 Data for Subcutaneous Migaldendranib at Angiogenesis 2025 Conference
Posted On Monday, February 10, 2025
Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH
Posted On Monday, February 10, 2025
Qu Biologics’ Immunomodulator Clears Senescence
Posted On Monday, February 10, 2025
Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma
Posted On Monday, February 10, 2025
Jasper Therapeutics Announces Briquilimab Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
Posted On Monday, February 10, 2025
Nutriband Receives Notice Of Allowance For New U.S. Patent Covering Its Transdermal Abuse Deterrent Technology Aversa™
Posted On Monday, February 10, 2025
Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
Posted On Monday, February 10, 2025

Print